ClinicalTrials.gg
RecruitingNCT05194423Updated Jan 18, 2022

THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein

An interventional study of Tricuspid Valve Replacement System via jugular vein in Tricuspid Valve Regurgitation, sponsored by Changhai Hospital. Recruiting at 9 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-01-18.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.

Planned enrollment
6th of 16
150 · median 129
Started
2022
with 3 others
No phase
15 of 28
9 open now
Primary completion
2027-03
later than 9 of 20 live
Registered
7th of 28
by date
Lead sponsor
2 of 28
Changhai Hospital

Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2022, is one of 15 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 7th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Tricuspid Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

The trial aims to evaluate the safety and effectiveness of LuX-Valve transcatheter tricuspid valve and delivery system via jugular vein which are intended to use in symptomatic patients with severe tricuspid regurgitation and high surgical risk.

Read the detailed description

The TRAVEL II study is a prospective multi-center single-arm trial for transcatheter tricuspid valve replacement with LuX-Valve via jugular vein. A series of physical, imaging and laboratory exams will be performed to determine whether a subject has severe tricuspid regurgitation with high surgical risk. Subjects who meet the criteria will then receive LuX-Valve implantation via jugular vein if an informed consent is obtained.

03

Conditions studied

  • Tricuspid Valve Regurgitation

Keywords

  • Tricuspid valve regurgitation
  • Transcatheter tricuspid valve replacement
  • LuX-Valve
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 50 years at time of consent.
  2. Subjects or subject's legal representative has been informed of the nature of the study and provided written .
  3. The site heart team confirmed the subject is at high risk for tricuspid valve surgery (euroSCORE II ≥ 7.0%) and the subject will get benefit from the intervention.
  4. Subjects must guarantee they won't participate in any other clinical trial for a period of one year after the intervention.
  5. Subjects are with (NYHA) Functional Class III or IV.
  6. Subjects are with normal left heart function (EF ≥ 50%).
  7. No indications for left-sided or pulmonary valve intervention.
  8. Subjects must have severe or greater tricuspid regurgitation ( the vena contracta (VC) width ≥ 7 mm or the effective regurgitant orifice area (EROA) ≥ 40 mm2), which confirmed by the Echocardiography Core Lab (ECL) via transthoracic echocardiogram (TTE).

Exclusion criteria

Exclusion Criteria:

  1. Subjects with pulmonary hypertension (systolic pressure ≥ 55mmHg determined by right heart catheterization).
  2. Subjects with previous transcatheter or surgical tricuspid valve procedure.
  3. Subjects with tricuspid stenosis or other anatomy disorders that unsuitable for the procedure.
  4. Subjects with depressed right heart function (tricuspid annular plane systolic excursion (TAPSE) \< 10mm or right ventricle fractional area change (FAC) \< 20%).
  5. Subjects with aortic stenosis (mean ΔP≥ 40mmHg or aortic valve area ≤ 1 cm2), aortic regurgitation (≥ 3+), mitral stenosis (mitral valve area ≤1.5 cm2) or mitral regurgitation (≥ 3+).
  6. Subjects with active endocarditis or other infectious diseases.
  7. Subjects with untreated severe coronary artery disease.
  8. Subjects with percutaneous coronary intervention, cerebrovascular accident or surgical intervention within 3 months of the date of the procedure.
  9. Subjects with coagulation disorders.
  10. Subjects with known allergy, or to the material or drugs used in the procedure.
  11. Subjects with cognitive disorders that can not cooperate the study or follow-up.
  12. Subjects with less than 12 months because of non-cardiac conditions.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Tricuspid Valve Replacement System via jugular vein

    Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system via jugular vein will be included in this arm.

    Device: Tricuspid Valve Replacement System via jugular vein

Interventions

  • DeviceTricuspid Valve Replacement System via jugular vein

    To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.

06

What researchers measure

Primary outcomes

  1. Death

    All-cause Death

    Time frame: 1 year

  2. Tricuspid Regurgitation Reduction

    Tricuspid regurgitation measured with echocardiography in core lab reduces at least 2 grades.

    Time frame: 1 year

Secondary outcomes

  1. Device or Procedure-Related Adverse Events

    Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.

    Time frame: 1 year

  2. Device or Procedure-Related Adverse Events

    Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.

    Time frame: 2 year

  3. Device or Procedure-Related Adverse Events

    Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.

    Time frame: 3 year

  4. Device or Procedure-Related Adverse Events

    Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.

    Time frame: 4 year

  5. Device or Procedure-Related Adverse Events

    Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.

    Time frame: 5 year

  6. Major Adverse Event (MAE)

    MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.

    Time frame: 1 year

  7. Major Adverse Event (MAE)

    MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.

    Time frame: 2 year

  8. Major Adverse Event (MAE)

    MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.

    Time frame: 3 year

  9. Major Adverse Event (MAE)

    MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.

    Time frame: 4 year

  10. Major Adverse Event (MAE)

    MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.

    Time frame: 5 year

  11. Functional Change in New York Heart Association (NYHA) Classification

    Subjects' heart function is ranged from NYHA I to IV based on how much a patient is limited during physical activity. NYHA I means no limited on physical activity while NYHA IV means unable to take any physical activity.

    Time frame: 1 year

  12. Change in Quality of Life (QOL) is evaluated with Kansas City Cardiomyopathy (KCCQ)

    KCCQ score ranges from 0 to 100, which 0 reflects the worst health status and 100 reflects the best health status.

    Time frame: 1 year

  13. Change in Quality of Life (QOL) is evaluated with Six Minute Walk Test (6MWT)

    6MWT distance is recorded and compared with baseline during follow-up.

    Time frame: 1 year

07

Study locations

2 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2022; primary completion for Mar 2027, 60 months later.

Of 86 interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2021
First posted
Jan 18, 2022
StartEst.
Mar 1, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jan 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05194423
Lead sponsor
Changhai Hospital
Responsible party
Zhiyun Xu (Chair of Department of Cardiovascular Surgery, Changhai Hospital) — Principal investigator
First posted
Jan 18, 2022
Start date
Mar 1, 2022 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 18, 2022

Study contacts

Fan Qiao, MD
Contact
qiaofan@smmu.edu.cn
+8613564620805
Fan Yang, MD
Contact
dearyangf@126.com
+8618321785183
Zhiyun Xu, MD
principal investigator · Changhai Hospital
Fanglin Lu, MD
study director · Changhai Hospital
Junbo Ge, MD
principal investigator · Shanghai Zhongshan Hospital
Shengshou Hu, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion